ATE350040T1 - Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin - Google Patents

Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin

Info

Publication number
ATE350040T1
ATE350040T1 AT00910474T AT00910474T ATE350040T1 AT E350040 T1 ATE350040 T1 AT E350040T1 AT 00910474 T AT00910474 T AT 00910474T AT 00910474 T AT00910474 T AT 00910474T AT E350040 T1 ATE350040 T1 AT E350040T1
Authority
AT
Austria
Prior art keywords
prostaglandin
pharmaceutical composition
nsaid
composition containing
composition
Prior art date
Application number
AT00910474T
Other languages
English (en)
Inventor
Aomar Ouali
Abul Kalam Azad
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Application granted granted Critical
Publication of ATE350040T1 publication Critical patent/ATE350040T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00910474T 1999-03-22 2000-03-20 Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin ATE350040T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/273,692 US6183779B1 (en) 1999-03-22 1999-03-22 Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin

Publications (1)

Publication Number Publication Date
ATE350040T1 true ATE350040T1 (de) 2007-01-15

Family

ID=23045012

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910474T ATE350040T1 (de) 1999-03-22 2000-03-20 Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin

Country Status (7)

Country Link
US (2) US6183779B1 (de)
EP (1) EP1162975B1 (de)
AT (1) ATE350040T1 (de)
AU (1) AU3269200A (de)
CA (1) CA2301378C (de)
DE (1) DE60032749T2 (de)
WO (1) WO2000056339A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6319519B2 (en) 1998-07-07 2001-11-20 Norton Healthcare Ltd. Anti-inflammatory pharmaceutical formulations
US6514525B2 (en) 1998-09-10 2003-02-04 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US6387410B1 (en) * 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
EP1216030A1 (de) * 1999-10-01 2002-06-26 Norton Healthcare Limited Entzündungshemmende pharmazeutische formulierungen
RU2277416C2 (ru) * 2000-03-21 2006-06-10 Ниппон Синяку Ко., Лтд. Препараты для перорального введения с замедленным высвобождением
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
US20020177626A1 (en) 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB2380937A (en) * 2001-10-18 2003-04-23 David Ian Slovick Method of dispensing a plurality of medical substances into capsules
DE10161077A1 (de) * 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
RU2196570C1 (ru) * 2001-12-13 2003-01-20 ЗАО "Медисорб" Фармацевтическая композиция, обладающая противовоспалительной активностью
GB2386817B (en) * 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
AU2003211146B2 (en) * 2002-02-21 2007-07-19 Valeant International (Barbados) Srl Controlled release dosage forms
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US20050124699A1 (en) * 2002-07-02 2005-06-09 Wakamoto Pharmaceutical Co., Ltd. Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US8992980B2 (en) * 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
WO2004064815A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
EP1462098B1 (de) * 2003-03-03 2007-07-04 SPRL Franpharma Stabilisierte pharmazeutische Zusammensetzung enthaltend einen NSAID und einen Prostaglandin
WO2004091579A1 (en) * 2003-04-16 2004-10-28 Pharmacia Corporation Stabilized prostaglandin formulation
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
EP1568369A1 (de) * 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam zur Behandlung von Atemwegserkrankungen bei Schweinen
DE102004021281A1 (de) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
DE102004030409A1 (de) * 2004-06-23 2006-01-26 Boehringer Ingelheim Vetmedica Gmbh Neue Verwendung von Meloxicam in der Veterinärmedizin
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
US20060177504A1 (en) * 2005-02-08 2006-08-10 Renjit Sundharadas Combination pain medication
US20070053868A1 (en) * 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
US20080187581A1 (en) * 2005-03-16 2008-08-07 Subhash Pandurang Gore Delivery System For Mulitple Drugs
US20070224259A1 (en) * 2005-09-21 2007-09-27 Gupta Anil K Anti-inflammatory pharmaceutical composition
EP1942902A1 (de) * 2005-09-30 2008-07-16 Boehringer Ingelheim Vetmedica Gmbh Meloxicam enthaltende pharmazeutische zubereitung
WO2007060540A1 (en) * 2005-11-25 2007-05-31 Aurobindo Pharma Limited Stable dosage forms of an antidepressant
NZ569813A (en) * 2005-12-16 2011-07-29 Hanmi Holdings Co Ltd Solid dispersion comprising an active ingredient having a low melting point and an absorbent, and a tablet for oral administration comprising same
WO2007093027A1 (en) * 2006-02-13 2007-08-23 Intelgenx Corp. Delayed release pharmaceutical oral dosage form and method of making same
EP2124556B1 (de) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
WO2008146178A2 (en) 2007-05-30 2008-12-04 Wockhardt Research Centre A novel tablet dosage form
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
CA2905541C (en) 2008-01-09 2020-02-11 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US20090214648A1 (en) * 2008-02-15 2009-08-27 Malathi Kandakatla Pharmaceutical formulations comprising ibuprofen and diphenhydramine
CN102131496B (zh) * 2008-08-22 2013-10-23 雷克特本克斯尔保健(英国)有限公司 组合物的改进或与组合物有关的改进
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
JP2012531409A (ja) 2009-06-25 2012-12-10 アストラゼネカ・アクチエボラーグ Ｎｓａｉｄ関連潰瘍を発症するリスクがある患者の処置方法
CN102638978A (zh) * 2009-06-25 2012-08-15 波曾公司 用于治疗需要阿司匹林治疗之患者的方法
EP3311667A1 (de) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
PL4378443T3 (pl) 2009-10-12 2025-09-08 Boehringer Ingelheim Vetmedica Gmbh Pojemniki na kompozycje zawierające meloksykam
CA2791805A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
CN102336693B (zh) * 2010-07-21 2014-01-22 上海天伟生物制药有限公司 卡前列素氨丁三醇的晶体及其制备方法和用途
US20140271783A1 (en) * 2011-10-14 2014-09-18 Purdue Research Foundation Prefabricated pharmaceutical dosage forms from functional polymer films
EP2797600A4 (de) 2011-12-28 2015-09-16 Pozen Inc Verbesserte zusammensetzungen und verfahren zur abgabe von omeprazol und acetylsalicylsäure
CN105435239B (zh) * 2014-08-29 2019-04-26 武汉光谷人福生物医药有限公司 美索舒利薄膜衣片及其制备方法
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3781429A (en) 1972-09-29 1973-12-25 American Cyanamid Co Method of inhibiting ulcerogenesis induced by non-steroidal anti-inflammatory agents
US3927213A (en) 1973-07-10 1975-12-16 American Home Prod Prostaglandin E{HD 2 {B and derivatives for reducing the side effects of anti-inflammatory agents
US3928588A (en) 1974-02-22 1975-12-23 Upjohn Co Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors
US3954787A (en) 1974-06-18 1976-05-04 Pfizer Inc. Stabilized E-series prostaglandins
US4301146A (en) 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
AU7876491A (en) 1990-05-03 1991-11-27 G.D. Searle & Co. Pharmaceutical composition
US5015481A (en) 1990-05-03 1991-05-14 G. D. Searle & Co. Stabilized pharmaceutical admixture composition
CN1277550A (zh) 1997-09-11 2000-12-20 尼科梅德丹麦有限公司 非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物
CA2241342C (en) 1998-06-15 2000-02-08 Bernard Charles Sherman Pharmaceutical tablets comprising an nsaid and a prostaglandin
GB9814215D0 (en) 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
GB9819685D0 (en) 1998-09-10 1998-11-04 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations

Also Published As

Publication number Publication date
DE60032749D1 (de) 2007-02-15
EP1162975B1 (de) 2007-01-03
EP1162975A1 (de) 2001-12-19
DE60032749T2 (de) 2007-10-18
CA2301378A1 (en) 2000-09-22
US6287600B1 (en) 2001-09-11
WO2000056339A1 (en) 2000-09-28
US6183779B1 (en) 2001-02-06
AU3269200A (en) 2000-10-09
CA2301378C (en) 2005-07-26

Similar Documents

Publication Publication Date Title
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
ATE215816T1 (de) Feste oral anzuwendende arzeneiform
NO20001290L (no) Multiple-enhet sammensetninger av ikke-steroid anti- inflammatorisk medikament substans (NSAID) med modifisert frigjøring
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
NO20061859L (no) OROS Push Stick for kontrollert tilforsel av aktive midler
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
JP2005515966A5 (de)
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
JP2006516570A5 (de)
NO20022014D0 (no) Kontrollert frigjöring av hydrocodone formuleringer
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
WO2003065982A3 (en) Engineering absorption of therapeutic compounds via colonic transporters
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
US7303761B2 (en) Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin
AP2003002763A0 (en) Controlled release formulations for oral administration
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
ATE430561T1 (de) Chronotherapeutische diltiazem formulierungen und deren verabreichung
JP2007509146A5 (de)
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
WO2007086079A3 (en) Sustained release dosage form of phenothiazine derivatives containing channelizer
JP2005525329A5 (de)
HUP0400495A2 (hu) Apomorfin szájnyálkahártyán keresztül történő adagolására szolgáló orális készítmény
JP2003523385A5 (de)
UY26176A1 (es) Formas polimorfas de un citrato de azobiciclo (2,2,2) octan- 3-amina y sus composiciones farmacéuticas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties